BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines gAAP Diluted Earnings (Loss) per ADS ($/ADS, 1 ADS = 13 Ordinary Shares) ($)
Form 10-Q / 10-K Consolidated Statements of Operations & Form 8-K Non-GAAP Reconciliations
Latest, Q2 2026
2.05
Period ended Jun 30, 2026
Change on a year earlier
+144.0%
0.84 in Q2 2025
History
18 quarters
Since Q1 2020
Sources
14
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GAAP Diluted Earnings (Loss) per ADS ($/ADS, 1 ADS = 13 Ordinary Shares) ($) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2.05 | +144.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 1.96 | +19,500.0% | Form 10-Q (filed 2026-05-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 1.09 | -194.8% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 0.84 | -173.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 0.01 | -100.4% | Form 10-Q (filed 2026-05-06) ↗ |
| Q3 2024 | Sep 30, 2024 | -1.15 | -157.2% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | -1.15 | -68.4% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | -2.41 | -27.8% | Form 10-Q (filed 2025-05-07) ↗ |
| Q3 2023 | Sep 30, 2023 | 2.01 | -137.3% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | -3.64 | -33.8% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | -3.34 | -21.4% | Form 10-Q (filed 2024-05-08) ↗ |
| Q3 2022 | Sep 30, 2022 | -5.39 | +14.2% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | -5.50 | +5.2% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | -4.25 | -715.9% | Form 10-Q (filed 2023-05-04) ↗ |
| Q3 2021 | Sep 30, 2021 | -4.72 | – | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | -5.23 | – | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 0.69 | -114.7% | Form 10-Q (filed 2021-05-06) ↗ |
| Q1 2020 | Mar 31, 2020 | -4.70 | – | Form 10-Q (filed 2021-05-06) ↗ |
Breakdown
What makes up gaap diluted earnings (loss) per ads ($/ads, 1 ads = 13 ordinary shares)
- GAAP Basic Earnings (Loss) per ADS ($/ADS)2.12 · Q2 2026
- Non-GAAP Adjusted Diluted Earnings (Loss) per ADS ($/ADS)3.84 · Q2 2026
- Non-GAAP Adjusted Basic Earnings (Loss) per ADS ($/ADS)3.98 · Q2 2026
- Non-GAAP Adjusted Diluted Earnings (Loss) per Ordinary Share ($/sh)0.30 · Q2 2026
- Non-GAAP Adjusted Basic Earnings (Loss) per Ordinary Share ($/sh)0.31 · Q2 2026
- Weighted-Average Diluted ADSs Outstanding (M ADSs)116 · Q2 2026
- Weighted-Average Basic ADSs Outstanding (M ADSs)112 · Q2 2026
Cite this data
StockData. (2026). BeOne Medicines GAAP Diluted Earnings (Loss) per ADS ($/ADS, 1 ADS = 13 Ordinary Shares) ($), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/eps_ads_diluted
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.